What the Company and Its Analysts Call “A Game”
Is Actually Illegal
Price Target $140
Citron predicts that after this report makes its rounds, TransDigm’s (NYSE:TDG) days of exploiting and deceiving the Federal Government are numbered.
Valeant Pharmaceuticals has recently hit prices that some never thought imaginable. As Citron observes today, at $12 per share, that stock is down over 95% from its highs just months prior to Citron’s reporting on Philidor. The questions then turn to:
“How did so many ‘smart’ people get it so wrong?”